

1. No funding from the Government is available to collaborator under a CRADA.

2. Non-exclusive license option available for background rights. Exclusive license rights may be available in a specified field of use.

3. One patent has been issued related to Adrenomedullin and PAMP and other related patent applications are pending.

4. In case, as a result of the CRADA work, a joint intellectual property is developed, the CRADA partner may have a right to file a joint patent application.

Patent Status and Pertinent References:

U.S. Provisional Patent Application Number 60/425,018, filed November 7, 2002, "A New Target for Angiogenesis and Anti-angiogenesis Therapy."

Patent Application Number PCT/US2003/035633, filed November 7, 2003, "A New Target for Angiogenesis and Anti-angiogenesis Therapy."

U.S. Provisional Application Serial No. 60/500,650 filed on 09/08/2003; "A new method to screen small molecule libraries and biologically active compounds that modulate adrenomedullin and gastrin releasing peptides." International Publication Number WO 2004/043383 A2, published May 27, 2004, "A New Target for Angiogenesis and Anti-angiogenesis Therapy."

López J, Martínez A. Cell and molecular biology of the multifunctional peptide, adrenomedullin. *International Review of Cytology* 221:1–92 (2002).

Martínez A, Vos M, Guédez L, Kaur G, Chen Z, Garayoa M, Pío R, Moody T, Stetler-Stevenson WG, Kleinman HK, Cuttitta F. The effects of adrenomedullin overexpression in breast tumor cells. *Journal of the National Cancer Institute* 94: 1226–1237 (2002).

Cuttitta F, Pío R, Garayoa M, Zudaire E, Julián M, Elsasser TH, Montuenga LM, Martínez A. Adrenomedullin functions as an important tumor survival factor in human carcinogenesis.

Microscopy Research and Technique 57:110–119 (2002).

Pío R, Martínez A, Cuttitta F. Cancer and diabetes: two pathological conditions in which adrenomedullin may be involved. *Peptides* 22:1719–1729 (2001).

Pío R, Martínez A, Unsworth EJ, Kowalak JA, Bengoechea JA, Zipfel PF, Elsasser TH, Cuttitta F. Complement factor H is a serum binding protein for adrenomedullin. The resulting complex modulates the bioactivities of both partners. *Journal of Biological Chemistry* 276:12292–12300 (2001).

Martínez A, Julián M, Bregonzio C, Notari L, Moody TW, Cuttitta F. Identification of vasoactive non-peptidic positive and negative modulators of adrenomedullin using a neutralizing monoclonal antibody-based screening strategy. *Endocrinology* 145:3858–3865 (2004).

Martínez A, Zudaire E, Portal-Núñez S, Guédez L, Libutti SK, Stetler-Stevenson WG, Cuttitta F. Proadrenomedullin—terminal 20 peptide is a potent angiogenic factor and its inhibition results in reduction of tumor growth. *Cancer Research* in press (2004).

Dated: August 25, 2004.

Karen Maurey,

Acting Chief, Technology Transfer Branch, National Cancer Institute, National Institutes of Health.

Dated: August 30, 2004.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 04–20291 Filed 9–7–04; 8:45 am]

BILLING CODE 4140–01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.


ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Integrin Alpha-V Beta-3 Antagonists for Use in Imaging and Therapy

S. Narasimhan Danthi *et al.* (CC), U.S. Patent Application filed 04 Aug 2004 (DHHS Reference No. E–170–2004/0–US–01).

Licensing Contact: Michael Shmilovich; 301/435–5019; shmilovm@mail.nih.gov.

Available for licensing are compounds as shown below for imaging and therapy. These compounds are integrin $\alpha_v\beta_3$ receptor antagonists and are described and claimed in a patent application available for review. The patent application also includes claim coverage for the administration of these compounds containing a detectable moiety or pharmaceutical compositions of such imaging agents as part of the imaging of cells that express integrin $\alpha_v\beta_3$.



In which: X is either NH, O, or S; n is zero or a positive integer; R₁ is either CH₂, NH, O, or S; R₂ is either CHR₇, NR₇, O, or S, in which R₇ is H or alkyl; R₃ and R₄, which are either the same or different from each other, are either H, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, alkyl-substituted aryl, (alkylsubstitutedaryl)alkyl, hydroxy-substituted alkyl, hydroxy-substituted aryl, or (hydroxy-substituted aryl)alkyl; R₅ is either CH₂, NH, O, or S; and R₆ is either H or C(=Y)-R₈-R₉, in which: Y is either NH, O, or S; R₈ is either CHR₁₀, NR₁₀, O, or S, in which R₁₀ is H or alkyl; and R₉ is either H, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, alkylsubstituted aryl, (alkyl-substituted aryl)alkyl, hydroxy-substituted alkyl, hydroxy-substituted aryl, or (hydroxy-substituted aryl)alkyl.

Use of Protein Kinase C Delta Inhibitor, Specifically Rottlerin, Alone or in Further Combination With Staurosporine, in the Treatment of Metastatic Epithelioid Melanoma

Denise Simmons (NCI), U.S. Provisional Application No. 60/531,876 filed 22 Dec 2003 (DHHS Reference No. E-311-2003/0-US-01).

Licensing Contact: Mojdeh Bahar; 301/435-2950; baharm@mail.nih.gov.

This invention is directed to the use of a protein kinase C delta inhibitor, specifically rottlerin, alone or in further combination with staurosporine, in the treatment of metastatic epithelioid melanoma. Preliminary studies show that treatment of cells from a metastasized human epithelioid melanoma with rottlerin reduced cellular proliferation by 90%, without

affecting proliferation or morphology of normal melanocytes. Cells from the matched primary site tumor of the same patient were not affected by this inhibitor, nor were cells from a matched tumor pair of fibroblastoid morphology obtained from a second patient. Treatment of cells from a metastasized human epithelioid melanoma with staurosporine caused an increase in branching and in the number of processes in the melanoma cells, without affecting cell number. These staurosporine-induced changes may be indicative of differentiation.

Dated: August 27, 2004.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 04-20293 Filed 9-7-04; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and

development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by contacting Susan Ano, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/435-5515; fax: 301/402-0220; e-mail: anos@mail.nih.gov. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Safer Attenuated Virus Vaccines With Missing or Diminished Latency of Infection

Jeffrey Cohen et al. (NIAID)

U.S. Provisional Application Filed 28 Jun 2004 (DHHS Reference No. E-217-2004/0-US-01)

This technology describes recombinant viruses that have weakened ability to establish and/or maintain latency and their use as live vaccines. The viruses have one or more genetic mutations that allow for continued replication but that inhibit latency. The vaccine materials and methods for their construction are exemplified with the virus that causes chickenpox and whose latent infection results in shingles, a condition that affects up to an estimated 1 million people per year in the United States alone. Additionally, there are veterinary